Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?

Vérane AchardSandra JorcanoMichel RouzaudLluís EscudéRaymond MiralbellThomas Zilli

Published in: Journal of cancer research and clinical oncology (2019)

In this retrospective hypothesis-generating analysis, less vs. more than 5 weeks OTT may increase acute and late GU toxicities without significantly improving bRFS in patients treated to high effective doses (> 80 Gy) with moderate hypofractionated RT. Prospective trials evaluating the impact of OTT on hypofractionated schedules for PCa are warranted.

Keyphrases

radiation therapy
prostate cancer
high intensity
radiation induced
brain metastases
locally advanced
liver failure
early stage
respiratory failure
small cell lung cancer
cross sectional
combination therapy
gestational age
extracorporeal membrane oxygenation
preterm birth
replacement therapy